Mirae Asset Global ETFs Holdings
MLTX icon

Mirae Asset Global ETFs Holdings’s MoonLake Immunotherapeutics MLTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,954
Closed -$85.7K – 3146
2025
Q3 		$85.7K Sell
11,954
-3,798
-24% -$198K ﹤0.01% 2732
2025
Q2 		$743K Buy
15,752
+1,819
+13% +$74.1K ﹤0.01% 1595
2025
Q1 		$544K Sell
13,933
-1,523
-10% -$65.6K ﹤0.01% 1828
2024
Q4 		$837K Buy
15,456
+1,866
+14% +$95.3K ﹤0.01% 1642
2024
Q3 		$685K Sell
13,590
-3,140
-19% -$147K ﹤0.01% 1752
2024
Q2 		$736K Buy
+16,730
New +$709K ﹤0.01% 1620

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's MLTX Position: Q4 2025 in Review

Mirae Asset Global ETFs Holdings sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 11,954 shares — an estimated $85.7K sold.

Mirae Asset Global ETFs Holdings first reported a position in MLTX in Q2 2024 and held it in 6 quarters. The position peaked at $837K in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 11,954 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $85.7K.
  • Mirae Asset Global ETFs Holdings first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 6 quarters.
  • Mirae Asset Global ETFs Holdings's MoonLake Immunotherapeutics position peaked at $837K in Q4 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.